LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

LLY

764.29

+2.02%↑

JNJ

176.51

-0.67%↓

ABBV

216.25

-0.31%↓

UNH

340.54

-2.38%↓

AZN

77.78

-0.23%↓

Search

Pacific Biosciences of California Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

1.24 3.33

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.17

Max

1.24

Pagrindiniai rodikliai

By Trading Economics

Pajamos

384M

-42M

Pardavimai

2.6M

40M

Pelno marža

-105.442

Darbuotojai

575

EBITDA

367M

-36M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+64.1% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-42M

375M

Ankstesnė atidarymo kaina

-2.09

Ankstesnė uždarymo kaina

1.24

Naujienos nuotaikos

By Acuity

100%

0%

358 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

Pacific Biosciences of California Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-15 22:39; UTC

Įsigijimai, susijungimai, perėmimai

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

2025-09-15 16:43; UTC

Pagrindinės rinkos jėgos

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

2025-09-15 16:42; UTC

Pagrindinės rinkos jėgos

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

2025-09-15 16:35; UTC

Pagrindinės rinkos jėgos

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

2025-09-15 23:46; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-15 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

2025-09-15 23:34; UTC

Rinkos pokalbiai

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

2025-09-15 22:48; UTC

Rinkos pokalbiai

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

2025-09-15 22:12; UTC

Įsigijimai, susijungimai, perėmimai

CSL Expects Commercial Launch in 2029

2025-09-15 22:12; UTC

Įsigijimai, susijungimai, perėmimai

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

2025-09-15 22:11; UTC

Įsigijimai, susijungimai, perėmimai

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

2025-09-15 22:11; UTC

Įsigijimai, susijungimai, perėmimai

CSL to Have Right to Exercise Option Based on Phase 3 Data

2025-09-15 22:10; UTC

Įsigijimai, susijungimai, perėmimai

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

2025-09-15 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

2025-09-15 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

2025-09-15 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy to Buy 48,000 Net Acres in the Williston Core

2025-09-15 21:14; UTC

Įsigijimai, susijungimai, perėmimai

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

2025-09-15 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-09-15 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-15 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-09-15 19:29; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

2025-09-15 19:14; UTC

Rinkos pokalbiai

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

2025-09-15 18:16; UTC

Rinkos pokalbiai

Gold Powers to New High -- Market Talk

2025-09-15 18:05; UTC

Rinkos pokalbiai

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

2025-09-15 17:50; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

2025-09-15 17:10; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-15 17:10; UTC

Rinkos pokalbiai

S&P Expects Fed, BOC to Cut Rates -- Market Talk

2025-09-15 16:52; UTC

Rinkos pokalbiai

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

2025-09-15 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-09-15 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Pacific Biosciences of California Inc Prognozė

Kainos tikslas

By TipRanks

64.1% į viršų

12 mėnesių prognozė

Vidutinis 1.92 USD  64.1%

Aukščiausias 3 USD

Žemiausias 1 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Pacific Biosciences of California Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

3

Pirkti

4

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.13 / N/APalaikymas ir pasipriešinimas

Trumpalaikis periodas

Bullish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

358 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat